Easier and more accessible testing for SARS-CoV-2 (COVID-19)
Ubiquitome has partnered with The SalivaDirect Initiative at Yale School of Public Health to enhance public access to COVID-19 testing, with United States Food and Drug Administration (FDA) emergency use authorization (EUA) of the combination of SalivaDirect™ with Ubiquitome’s Liberty16 mobile real time-PCR.
In Yale School of Public Health testing the Liberty16 displayed performance similar to large, lab-bound instruments.
|Proteinase K||Primer/Probe||RT-qPCR kit||RT-qPCR instrument||LOD||Positive replicates||Mean Ct value (SD)|
|Thermo||IDT||NEB Luna (2x)||Agilent AriaMX||6 copies/μL||100% (20/20)||30.3 (0.4)|
|Thermo||Eurofins||NEB Luna (2x)||Liberty16||12 copies/μL||100% (20/20)||35.18 (0.7)|
|Thermo||IDT||NEB Luna (2x)||CFX384 Touch||6 copies/μL||100% (20/20)||36.25 (0.4)|
Liberty16 Workplace Surveillance Testing for COVID-19
Now available for small and medium sized workplaces, with affordable on-site gold standard PCR testing to keep costs down, productivity up and your staff COVID safe.
NIH RADx winner’s next gen Liberty16 Pro gets EUA Auckland, December 19, 2022: Ubiquitome’s next generation real time PC...
"Costly instruments for real-time PCR analysis often stand in the way of equitable access for under resourced communities and countries and sustainability of testing systems"